Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

IRLAB Therapeutics

1.98 SEK-4.48 %22.10, 17.29
Less than 1K followers

IRLAB A

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-4.48 %
+13.91 %
+47.03 %
+33.25 %
+2.81 %
-18.98 %
-68.82 %
-95.07 %
-81.50 %

IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.

Read more
Market cap
294.75M SEK
Turnover
1.24M SEK
Revenue
57.46M
EBIT %
-162.55 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
13.11
2026

Interim report Q3'26

12.2
2027

Annual report '26

All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release20.10.2026, 15.00

Nomination committee appointed for IRLAB’s annual general meeting 2027

IRLAB Therapeutics
Press release20.10.2026, 07.00

IRLAB’s Preclinical Research Underpinning Linepemat Published in Peer-Reviewed Journal

IRLAB Therapeutics
Press release09.10.2026, 07.00

IRLAB to present at Redeye Theme: Neurology

IRLAB Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release24.09.2026, 17.30

IRLAB Appoints Janne Backman as New Chairman of the Board

IRLAB Therapeutics
Regulatory press release03.09.2026, 10.55

IRLAB’s CEO intends to step down during the first quarter of 2027

IRLAB Therapeutics
Regulatory press release31.08.2026, 07.00

New number of shares and votes in IRLAB Therapeutics AB

IRLAB Therapeutics
Press release28.08.2026, 18.28

Redeye: IRLAB (Q2 Review): Partnering remains in focus

IRLAB Therapeutics
Regulatory press release26.08.2026, 07.00

IRLAB publishes interim report for the period January - June 2026

IRLAB Therapeutics
Press release20.08.2026, 12.00

IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast

IRLAB Therapeutics
Press release19.08.2026, 07.00

IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO

IRLAB Therapeutics
Regulatory press release31.07.2026, 07.00

New number of shares and votes in IRLAB Therapeutics AB

IRLAB Therapeutics
Press release10.07.2026, 15.30

IRLAB’s rights issue is registered – conversion of BTA into shares

IRLAB Therapeutics
Regulatory press release30.06.2026, 17.10

Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB

IRLAB Therapeutics
Regulatory press release29.06.2026, 20.45

IRLAB’s rights issue was oversubscribed and the company resolves on allotment in the overallotment issue

IRLAB Therapeutics
Press release16.06.2026, 07.00

IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies

IRLAB Therapeutics
Regulatory press release11.06.2026, 08.45

The subscription period in IRLAB’s rights issue commences today

IRLAB Therapeutics
Regulatory press release05.06.2026, 16.00

IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received

IRLAB Therapeutics
Regulatory press release05.06.2026, 13.50

Report from the Extraordinary General Meeting of IRLAB Therapeutics AB

IRLAB Therapeutics
Press release03.06.2026, 07.00

IRLAB participates at Aktiedagarna in Stockholm on June 9.

IRLAB Therapeutics
Regulatory press release06.05.2026, 07.00

IRLAB publishes interim report for the period January - March 2026

IRLAB Therapeutics